Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Fabi

Showing results (231-240 of 265) with videos related to

Pageof 27
Sort By:
Journal of the National Cancer Institute|March 28, 2026
Temporal Patterns and Factors Associated with Early Termination in Phase 1 Clinical Trials for Solid TumorsGiovanni Maria Iannantuono, Stefano Sganga, Tommaso Giovagnoli, et al.
Breast Cancer Research and Treatment|March 30, 2017
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experienceMariangela Ciccarese, Alessandra Fabi, Luca Moscetti, et al.
Breast Cancer Research : BCR|October 29, 2022
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER studyNicla La Verde, Giovanna Damia, Ornella Garrone, et al.
Eclinicalmedicine|April 30, 2024
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trialsEva Blondeaux, Wanling Xie, Luca Carmisciano, et al.
Cancers|December 30, 2025
Pregnancy vs. Postpartum Breast Cancer: Distinct Tumor Biology and Survival Trends in a Contemporary CohortElena Jane Mason, Alba Di Leone, Beatrice Carnassale, et al.
The Lancet. Oncology|September 20, 2021
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trialLucia Del Mastro, Mauro Mansutti, Giancarlo Bisagni, et al.
Oncotarget|October 4, 2017
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter studyAlessandra Fabi, Michelino De Laurentiis, Michele Caruso, et al.
Breast (Edinburgh, Scotland)|May 29, 2026
Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER studyLetizia Pontolillo, Elisabetta Munzone, Paolo Vigneri, et al.
The Oncologist|November 23, 2023
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL StudyAndrea Botticelli, Roberta Caputo, Simone Scagnoli, et al.
Life (Basel, Switzerland)|April 26, 2025
Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives on Primary Sarcomas and Malignant Phyllodes TumorsFlavia De Lauretis, Alejandro Martin Sanchez, Cristina Accetta, et al.
Pageof 27

Showing results (231-240 of 265) with videos related to

Sort By:
Pageof 27
Journal of the National Cancer Institute|March 28, 2026
Temporal Patterns and Factors Associated with Early Termination in Phase 1 Clinical Trials for Solid TumorsGiovanni Maria Iannantuono, Stefano Sganga, Tommaso Giovagnoli, et al.
Breast Cancer Research and Treatment|March 30, 2017
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experienceMariangela Ciccarese, Alessandra Fabi, Luca Moscetti, et al.
Breast Cancer Research : BCR|October 29, 2022
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER studyNicla La Verde, Giovanna Damia, Ornella Garrone, et al.
Eclinicalmedicine|April 30, 2024
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trialsEva Blondeaux, Wanling Xie, Luca Carmisciano, et al.
Cancers|December 30, 2025
Pregnancy vs. Postpartum Breast Cancer: Distinct Tumor Biology and Survival Trends in a Contemporary CohortElena Jane Mason, Alba Di Leone, Beatrice Carnassale, et al.
The Lancet. Oncology|September 20, 2021
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trialLucia Del Mastro, Mauro Mansutti, Giancarlo Bisagni, et al.
Oncotarget|October 4, 2017
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter studyAlessandra Fabi, Michelino De Laurentiis, Michele Caruso, et al.
Breast (Edinburgh, Scotland)|May 29, 2026
Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER studyLetizia Pontolillo, Elisabetta Munzone, Paolo Vigneri, et al.
The Oncologist|November 23, 2023
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL StudyAndrea Botticelli, Roberta Caputo, Simone Scagnoli, et al.
Life (Basel, Switzerland)|April 26, 2025
Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives on Primary Sarcomas and Malignant Phyllodes TumorsFlavia De Lauretis, Alejandro Martin Sanchez, Cristina Accetta, et al.
Pageof 27